CSL Bering Gets FDA Orphan Designation for Hizentra

Date : 12/09/2019 @ 2:12PM
Source : Dow Jones News
Stock : CSL Limited (CSL)
Quote : 311.28  1.84 (0.59%) @ 7:49AM

CSL Bering Gets FDA Orphan Designation for Hizentra

CSL (ASX:CSL)
Historical Stock Chart

2 Months : From Nov 2019 to Jan 2020

Click Here for more CSL Charts.

By Colin Kellaher

 

CSL Ltd.'s (CSL.AU) CSL Behring unit Monday said it received orphan-drug exclusivity from the U.S. Food and Drug Administration for Hizentra as maintenance therapy to prevent relapse of neuromuscular disability and impairment in adults with chronic inflammatory demyelinating polyneuropathy, or CIDP.

CSL said the decision provides a seven-year period of U.S. marketing exclusivity for Hizentra in the maintenance treatment of CIDP with subcutaneous immunoglobulin.

The FDA in March 2018 approved Hizentra to prevent relapse of neuromuscular disability and impairment in adults with CIDP, a rare autoimmune disorder that affects the peripheral nerves and has the potential to cause significant disability.

The FDA's orphan-drug program gives special status to drugs and biologics for diseases and disorders that affect fewer than 200,000 people in the U.S.

 

Write to Colin Kellaher at colin.kellaher@wsj.com

 

(END) Dow Jones Newswires

December 09, 2019 08:57 ET (13:57 GMT)

Copyright (c) 2019 Dow Jones & Company, Inc.


Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.


NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.